Novartis Onbrez Breezhaler study shows improvement in lung function
Patients with COPD using the new Onbrez Breezhaler were also able to reduce their use of rescue medication compared to those using salmeterol, a widely prescribed drug in
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The 12-week, randomised, double-blind, multicenter Phase III study demonstrated that Lixisenatide was safe and well tolerated in patients with type 2 diabetes. The trial result suggested that Lixisenatide